Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 3Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Dermatologic 1

Conditions

Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Leukemia, T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × forodesine × Clear all
NCT00289549 2012-02-08

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

BioCryst Pharmaceuticals

Phase 2 Completed
8 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00501735 2012-01-23

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

BioCryst Pharmaceuticals

Phase 2 Completed
144 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

NCT00095381 2012-01-19

Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia

BioCryst Pharmaceuticals

Phase 2 Completed
20 enrolled
LymphoidOther hematologic neoplasm

Leukemia, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡